Farmington, April 25, 2023 (GLOBE NEWSWIRE) -- The Hereditary Angioedema Market size was valued at USD 2431.89 Million in 2022 and is projected to reach USD 4881.37 Million by 2030, growing at a CAGR of 9.10% from 2023 to 2030. The Hereditary Angioedema Association is predicted to play an important role in spreading new therapies around the world. They have also attempted to raise awareness of products and enhance the benefits that HAE patients need, which is expected to lead to a positive change in the Hereditary Angioedema industry. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead. Nonetheless, high drug prices and delayed detection of illnesses are some of the variables limiting the growth of the Hereditary Angioedema market during the forecast period.
Request Sample Copy of Report “ Hereditary Angioedema Market - Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Covid-19 Impact, SWOT Analysis, Competition and Forecasts 2022 to 2030”, published by Contrive Datum Insights.
Segmentation Overview:
Type Outlook:
Based on the drug class, the Hereditary Angioedema Therapeutics market can be segmented as C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and others. During the forecast timeline, the C1-esterase inhibitor segment would be the largest. The use of the drugs of both on-demand and prophylactic management of HAE accounts for the majority of the segment's revenue.
Application Outlook:
Based on treatment type, the hereditary angioedema therapeutics market is divided into prophylaxis and on-demand. In the years ahead, on-demand treatment would have the highest market share. A higher intensity rendering engine for the hereditary angioedema therapeutics industry is the continued use of on-demand drugs for the treatment of acute hereditary angioedema attacks. Furthermore, corporations' regional expansion into newer markets is likely to aid segment growth.
Regional Analysis:
North America accounted for a leading share in the market in terms of revenue in 2018 owing to new product launches by major players, better reimbursement scenario, and well-developed healthcare infrastructure. For instance, in February 2018, the FDA granted regulatory approval for Cinryze for expanded application in pediatric patients aged 6 years and above. Asia Pacific is expected to witness the fastest growth during the forecast period. Growing patient awareness levels, coupled with the launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region.
Buy this Premium Research Report@
https://www.contrivedatuminsights.com/buy/8142
Scope of Report:
| Report Attributes | Details |
| Growth Rate | CAGR of 9.1% % from 2023 to 2030. |
| Revenue Forecast by 2030 | USD 4,881.37 Million |
| By Type |
|
| By Application |
|
| By Industries |
|
| By Companies |
|
| Regions and Countries Covered |
|
| Base Year | 2022 |
| Historical Year | 2017 to 2022 |
| Forecast Year | 2023 to 2030 |
Market Dynamics:
Restraint
The major factors that hinder growth of the global hereditary angioedema market include possibility of misdiagnosis of hereditary angioedema and high cost of drugs used for angioedema treatment. For instance, according to an article published by Everyday Health, Inc., in June 2020, people with hereditary angioedema (HAE) are often misdiagnosed as having another medical problem. According to the same source, in a survey of 313 patients, 65 percent of those with HAE reported being misdiagnosed before a doctor accurately identified their condition. HAE is commonly mistaken for an allergic reaction, appendicitis, and irritable bowel syndrome (IBS). About 40 percent of people with HAE are diagnosed within the first three years whereas almost 33 percent of people still face delays of 10 years or longer
Dynamics
The growth of the hereditary angioedema market is primarily driven by rising incidences of hereditary angioedema across geographies. Growing emphasis on initiatives aimed at creating awareness among consumers related to the disease is expected to augment the market growth substantially. In addition to this, increasing investment in research and development activities to develop a novel drug is likely to create lucrative opportunities for the players operating in the global hereditary angioedema market in the coming years.
Key Segments Covered:
Top Market Players:
- Pharming Group NV
- Shire plc
- CSL Limited
- iBio Inc.
- BioCryst Pharmaceuticals
- Others.
By Type
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
By Application
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Industries
- Government
- Healthcare
- Retail
- Manufacturing
- Others
Regions and Countries Covered
- North America: (US, Canada, Mexico, Rest of North America)
- Europe: (Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe)
- Asia-Pacific: (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific)
- The Middle East & Africa: (Saudi Arabia, UAE, Egypt, South Africa, Rest of the Middle East & Africa)
- Latin America: (Brazil, Argentina, Rest of Latin America)
- Rest Of the World
Check out more related studies published by Contrive Datum Insights:
- Ragweed Pollen Allergy Treatment Market - The Global Ragweed Pollen Allergy Treatment Market Is Estimated To Be Valued At USD 836.9 Million By 2022 And Is Projected To Register A CAGR Of 4.6% During The Forecast Period.
- Breast Cancer Market - The global Breast Cancer Market size was estimated at USD 31.89 Billion in 2022 and is projected to hit around USD 70.51 Billion by 2030 with a registered CAGR of 10.43% during the forecast period 2022 to 2030.
- Single-use Bioreactors Market- The Global single-use bioreactor market was valued at US$ 3.30 Billion in 2022, and is projected to reach US$ 12.06 Billion by 2030, growing at a CAGR of 17.19% from 2023 to 2030.
Customization of the Report: The report can be customized as per client needs or requirements.For any queries, you can contact us on anna@contrivedatuminsights.com or +1 215-297-4078. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.
Social: Facebook / LinkedIn / Twitter
Contact Us:
Anna B. | Head Of Sales
Contrive Datum Insights
Phone: +91 9834816757 | +1 2152974078
Email: anna@contrivedatuminsights.com
Website:
https://www.contrivedatuminsights.com
Contrive Datum Insights Press Releases
Latest Contrive Datum Insights Latest Reports
